Short Interest in Apollomics Inc. (NASDAQ:APLM) Decreases By 28.9%

Apollomics Inc. (NASDAQ:APLM) was the recipient of a significant decrease in short interest in April. As of April 15th, there was short interest totaling 6,089 shares, a decrease of 28.9% from the March 31st total of 8,562 shares. Approximately 0.6% of the shares of the company are short sold. Based on an average trading volume of 14,354 shares, the short-interest ratio is currently 0.4 days.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Apollomics stock. Kestra Advisory Services LLC bought a new stake in Apollomics Inc. (NASDAQ:APLM) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 4,380 shares of the company’s stock, valued at approximately $82,000. Kestra Advisory Services LLC owned about 0.40% of Apollomics as of its most recent SEC filing. 19.13% of the stock is owned by institutional investors.

Apollomics Price Performance

APLM opened at $12.95 on Tuesday. Apollomics has a 52 week low of $3.66 and a 52 week high of $42.12. The business’s fifty day simple moving average is $17.50 and its 200 day simple moving average is $18.38.

Wall Street Analyst Weigh In

APLM has been the topic of several recent research reports. Wall Street Zen upgraded Apollomics from a “sell” rating to a “hold” rating in a research report on Saturday, January 17th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Apollomics in a research report on Friday, March 27th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company has a consensus rating of “Sell”.

Apollomics Company Profile

Apollomics, Inc, a clinical-stage biopharmaceutical company based in Palo Alto, California, focuses on the development of innovative targeted therapies and immuno-oncology agents for the treatment of cancer. The company’s research and development efforts center on small molecule inhibitors and monoclonal antibodies designed to address key pathways involved in tumor growth and immune evasion. Its lead asset, dalpiciclib (formerly SHP654), is a selective oral CDK4/6 inhibitor in Phase III trials for metastatic breast cancer, and Apollomics holds a number of additional early-stage programs targeting solid tumors and hematologic malignancies.

Founded in 2015, Apollomics has established research and clinical collaboration networks across North America, China and Europe.